The Intestinal Microbiota in Inflammatory Bowel Disease.

The intestinal microbiota has important metabolic and host-protective functions. Conversely to these beneficial functions, the intestinal microbiota is thought to play a central role in the etiopathogenesis of inflammatory bowel disease (IBD; Crohn's disease and ulcerative colitis), a chronic inflammation of the gut mucosa. Genetic screens and studies in experimental mouse models have clearly demonstrated that IBD can develop due to excessive translocation of bacteria into the bowel wall or dysregulated handling of bacteria in genetically susceptible hosts. In healthy individuals, the microbiota is efficiently separated from the mucosal immune system of the gut by the gut barrier, a single layer of highly specialized epithelial cells, some of which are equipped with innate immune functions to prevent or control access of bacterial antigens to the mucosal immune cells. It is currently unclear whether the composition of the microbial flora or individual bacterial strains or pathogens induces or supports the pathogenesis of IBD. Further research will be necessary to carefully dissect the contribution of individual bacterial species to this disease and to ascertain whether specific modulation of the intestinal microbiome may represent a valuable further option for future therapeutic strategies.

[1]  H. Rafa,et al.  Mucosal intestinal alteration in experimental colitis correlates with nitric oxide production by peritoneal macrophages: Effect of probiotics and prebiotics , 2012, Immunopharmacology and immunotoxicology.

[2]  Sarah L. Brown,et al.  A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells , 2008, Nature.

[3]  Se Jin Song,et al.  The treatment-naive microbiome in new-onset Crohn's disease. , 2014, Cell host & microbe.

[4]  R. Xavier,et al.  Virus-Plus-Susceptibility Gene Interaction Determines Crohn's Disease Gene Atg16L1 Phenotypes in Intestine , 2010, Cell.

[5]  Alastair Forbes,et al.  Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease , 2008, Nature Genetics.

[6]  R. Bibiloni,et al.  The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. , 2006, Journal of medical microbiology.

[7]  P. Bozko,et al.  The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? , 2013, Therapeutic advances in gastroenterology.

[8]  V. Deretic,et al.  Autophagy Is a Defense Mechanism Inhibiting BCG and Mycobacterium tuberculosis Survival in Infected Macrophages , 2004, Cell.

[9]  R. Knight,et al.  Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns , 2010, Proceedings of the National Academy of Sciences.

[10]  E. Mann,et al.  Gastrointestinal infection as a trigger for inflammatory bowel disease , 2012, Current opinion in gastroenterology.

[11]  Maria Karlsson,et al.  Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. , 2010, Cell host & microbe.

[12]  D. Golenbock,et al.  Induction of Persistent Colitis by a Human Commensal, Enterotoxigenic Bacteroides fragilis, in Wild-Type C57BL/6 Mice , 2009, Infection and Immunity.

[13]  I. Martínez,et al.  Long-Term Temporal Analysis of the Human Fecal Microbiota Revealed a Stable Core of Dominant Bacterial Species , 2013, PloS one.

[14]  Thomas Lengauer,et al.  A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1 , 2007, Nature Genetics.

[15]  M. Netea,et al.  NOD2 and Toll-Like Receptors Are Nonredundant Recognition Systems of Mycobacterium tuberculosis , 2005, PLoS pathogens.

[16]  R. Knight,et al.  Diversity, stability and resilience of the human gut microbiota , 2012, Nature.

[17]  N. Barnich,et al.  Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. , 1998, Gastroenterology.

[18]  A. Gasbarrini,et al.  Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study , 2010, The American Journal of Gastroenterology.

[19]  M. Neurath,et al.  Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens. , 1999, Journal of immunology.

[20]  Antonio Gasbarrini,et al.  Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection: A Systematic Review , 2014, Journal of clinical gastroenterology.

[21]  Judy H. Cho,et al.  A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.

[22]  Rafael Bargiela,et al.  Gut microbiota disturbance during antibiotic therapy: a multi-omic approach , 2012, Gut.

[23]  Judy H. Cho,et al.  [Letters to Nature] , 1975, Nature.

[24]  K. Fellermann,et al.  Human defensins in Crohn's disease. , 2005, Chemical immunology and allergy.

[25]  A. Di Leo,et al.  Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? , 2014, World journal of gastrointestinal pathophysiology.

[26]  P. Brigidi,et al.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. , 2000, Gastroenterology.

[27]  A. Sher,et al.  Bacteria-triggered CD4+ T Regulatory Cells Suppress Helicobacter hepaticus–induced Colitis , 2002, The Journal of experimental medicine.

[28]  J. Galmiche,et al.  Saccharomyces boulardii does not prevent relapse of Crohn's disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[30]  J. Heimbach,et al.  Novel probiotics and prebiotics: road to the market. , 2015, Current opinion in biotechnology.

[31]  K. Gradel,et al.  Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. , 2009, Gastroenterology.

[32]  E. Purdom,et al.  Diversity of the Human Intestinal Microbial Flora , 2005, Science.

[33]  M. Chamaillard,et al.  Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition , 2004, The EMBO journal.

[34]  R. Sartor,et al.  Resident Enteric Bacteria Are Necessary for Development of Spontaneous Colitis and Immune System Activation in Interleukin-10-Deficient Mice , 1998, Infection and Immunity.

[35]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.

[36]  S. Ng,et al.  Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease , 2011, Gut.

[37]  A. Forbes,et al.  Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease , 2005, Gut.

[38]  P. Rutgeerts,et al.  Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum , 1991, The Lancet.

[39]  E. El-Omar,et al.  The role of infection in the aetiology of inflammatory bowel disease , 2010, Journal of Gastroenterology.

[40]  Timothy L. Tickle,et al.  Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment , 2012, Genome Biology.

[41]  B. Roe,et al.  A core gut microbiome in obese and lean twins , 2008, Nature.

[42]  R. Hammer,et al.  The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats , 1994, The Journal of experimental medicine.

[43]  E. El-Omar,et al.  Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? , 2014, World journal of gastroenterology.

[44]  J. Clemente,et al.  Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome? , 2015, Expert review of gastroenterology & hepatology.

[45]  R Balfour Sartor,et al.  Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. , 2004, Gastroenterology.

[46]  P. Bork,et al.  Richness of human gut microbiome correlates with metabolic markers , 2013, Nature.

[47]  Helmut Neumann,et al.  Caspase-8 regulates TNF-alpha induced epithelial necroptosis and terminal ileitis , 2011, Nature.

[48]  R. Sartor,et al.  Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment , 2000, Gut.

[49]  J. Rhodes,et al.  The role of bacteria in the pathogenesis of inflammatory bowel disease. , 2010, Gut and liver.

[50]  H. Kiyono,et al.  Epithelial barrier: an interface for the cross‐communication between gut flora and immune system , 2012, Immunological reviews.

[51]  Thomas Lengauer,et al.  Genetic variation in DLG5 is associated with inflammatory bowel disease , 2004, Nature Genetics.

[52]  J. Galán,et al.  Salmonella Modulation of Host Cell Gene Expression Promotes Its Intracellular Growth , 2013, PLoS pathogens.

[53]  J. Nicholson,et al.  Host-Gut Microbiota Metabolic Interactions , 2012, Science.

[54]  C. Josenhans,et al.  The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models , 2010, Nature Reviews Microbiology.

[55]  K. Madsen,et al.  Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. , 1999, Gastroenterology.

[56]  N. Socci,et al.  Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. , 2010, The Journal of clinical investigation.

[57]  W. Michalski,et al.  Mycobacterium avium subspecies paratuberculosis in children with early‐onset Crohn's disease , 2009, Inflammatory bowel diseases.

[58]  S. Mazmanian,et al.  A pathobiont of the microbiota balances host colonization and intestinal inflammation. , 2010, Cell host & microbe.

[59]  M. Netea,et al.  Mycobacterium paratuberculosis is recognized by Toll‐like receptors and NOD2 , 2007, Journal of leukocyte biology.

[60]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[61]  M. Surette,et al.  Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. , 2015, Gastroenterology.

[62]  S. Yamaoka,et al.  Nod2, a Nod1/Apaf-1 Family Member That Is Restricted to Monocytes and Activates NF-κB* , 2001, The Journal of Biological Chemistry.

[63]  C. Pothoulakis,et al.  Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. , 2007, Gastroenterology.

[64]  W. Selby,et al.  Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. , 2007, Gastroenterology.

[65]  M. Kamm,et al.  Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis , 2006, Gut.

[66]  J. Sanderson,et al.  Mycobacterium paratuberculosis DNA in Crohn's disease tissue. , 1992, Gut.

[67]  A. Izeta,et al.  On the Prevalence of M. avium Subspecies paratuberculosis DNA in the Blood of Healthy Individuals and Patients with Inflammatory Bowel Disease , 2008, PloS one.

[68]  Dan R. Littman,et al.  Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria , 2009, Cell.

[69]  M. Weichenthal,et al.  Reduced Paneth cell α-defensins in ileal Crohn's disease , 2005 .

[70]  P. Mannon,et al.  The fundamental basis of inflammatory bowel disease. , 2007, The Journal of clinical investigation.

[71]  A. Kostic,et al.  The microbiome in inflammatory bowel disease: current status and the future ahead. , 2014, Gastroenterology.

[72]  R. Sartor,et al.  Helicobacter hepaticus Does Not Induce or Potentiate Colitis in Interleukin-10-Deficient Mice , 2000, Infection and Immunity.

[73]  N. Pace,et al.  Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases , 2007, Proceedings of the National Academy of Sciences.

[74]  M. Dave,et al.  The human gut microbiome: current knowledge, challenges, and future directions. , 2012, Translational research : the journal of laboratory and clinical medicine.

[75]  J. Clemente,et al.  Human gut microbiome viewed across age and geography , 2012, Nature.

[76]  Y. Belkaid,et al.  Effector and memory T cell responses to commensal bacteria. , 2013, Trends in immunology.

[77]  Sang-Uk Seo,et al.  Role of the gut microbiota in immunity and inflammatory disease , 2013, Nature Reviews Immunology.

[78]  J. Blanco,et al.  Molecular diversity of Escherichia coli in the human gut: New ecological evidence supporting the role of adherent‐invasive E. coli (AIEC) in Crohn's disease , 2009, Inflammatory bowel diseases.

[79]  C. Prantera,et al.  Antibiotics and Inflammatory Bowel Diseases , 2013, Digestive Diseases.

[80]  M. Neurath,et al.  Epithelial NEMO links innate immunity to chronic intestinal inflammation , 2007, Nature.

[81]  A. Izeta,et al.  Lactase persistence, NOD2 status and Mycobacterium avium subsp. paratuberculosis infection associations to Inflammatory Bowel Disease , 2012, Gut Pathogens.

[82]  Julian Parkhill,et al.  High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease , 2011, BMC Microbiology.

[83]  C. Huttenhower,et al.  Inflammatory bowel disease as a model for translating the microbiome. , 2014, Immunity.

[84]  P. Bork,et al.  A human gut microbial gene catalogue established by metagenomic sequencing , 2010, Nature.

[85]  D. Fan,et al.  Fecal microbiota transplantation through mid‐gut for refractory Crohn's disease: Safety, feasibility, and efficacy trial results , 2015, Journal of gastroenterology and hepatology.

[86]  Tomas Hrncir,et al.  Nod2 is required for the regulation of commensal microbiota in the intestine , 2009, Proceedings of the National Academy of Sciences.

[87]  K. Plein,et al.  Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study. , 1993, Zeitschrift fur Gastroenterologie.

[88]  S. Dalal,et al.  The microbial basis of inflammatory bowel diseases. , 2014, The Journal of clinical investigation.

[89]  A. Sood,et al.  The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[90]  P. Brigidi,et al.  Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial , 2000, Gastroenterology.

[91]  T. Matsui,et al.  Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease , 2012, Journal of Gastroenterology.

[92]  Aristides G. Eliopoulos,et al.  The gut microbiota in mouse models of inflammatory bowel disease , 2014, Front. Cell. Infect. Microbiol..

[93]  K. Taylor,et al.  Genome-Wide Association , 2007, Diabetes.

[94]  E. Zoetendal,et al.  Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. , 2015, Gastroenterology.

[95]  Wendy S. Garrett,et al.  Communicable Ulcerative Colitis Induced by T-bet Deficiency in the Innate Immune System , 2007, Cell.

[96]  C. Obled,et al.  Oligosaccharides isolated from goat milk reduce intestinal inflammation in a rat model of dextran sodium sulfate-induced colitis. , 2006, Clinical nutrition.

[97]  C. Manichanh,et al.  Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach , 2005, Gut.

[98]  James P. Nataro,et al.  Diarrheagenic Escherichia coli , 1998, Clinical Microbiology Reviews.

[99]  J. Ward,et al.  Inflammatory large bowel disease in immunodeficient mice naturally infected with Helicobacter hepaticus. , 1996, Laboratory animal science.

[100]  E. Zoetendal,et al.  Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. , 2015, World journal of gastroenterology.

[101]  J. Valentine,et al.  Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease , 2004, The Lancet.

[102]  M. Trauner,et al.  Temporal Bacterial Community Dynamics Vary Among Ulcerative Colitis Patients After Fecal Microbiota Transplantation , 2013, The American Journal of Gastroenterology.

[103]  F. Shanahan,et al.  Role of interleukin (IL‐10) in probiotic‐mediated immune modulation: an assessment in wild‐type and IL‐10 knock‐out mice , 2006, Clinical and experimental immunology.

[104]  Zhang Sb,et al.  Analysis of the c- kit gene in patients with slow transit constipation , 2005 .

[105]  C. Neut,et al.  Dysbiosis as a prerequisite for IBD. , 2004, Gut.

[106]  Daniel B. DiGiulio,et al.  Development of the Human Infant Intestinal Microbiota , 2007, PLoS biology.

[107]  J M Ward,et al.  Helicobacter hepaticus Triggers Colitis in Specific-Pathogen-Free Interleukin-10 (IL-10)-Deficient Mice through an IL-12- and Gamma Interferon-Dependent Mechanism , 1998, Infection and Immunity.

[108]  J. Clemente,et al.  The Long-Term Stability of the Human Gut Microbiota , 2013 .

[109]  H A Malchow,et al.  Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? , 1997, Journal of clinical gastroenterology.

[110]  A. Franke,et al.  The genetics of Crohn’s disease and ulcerative colitis – status quo and beyond , 2015, Scandinavian journal of gastroenterology.

[111]  J. Harel,et al.  Adherent and Invasive Escherichia coli Is Associated with Granulomatous Colitis in Boxer Dogs , 2006, Infection and Immunity.

[112]  S. Mazmanian,et al.  Microbial learning lessons: SFB educate the immune system. , 2014, Immunity.

[113]  P. Testoni,et al.  Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease , 2000, Digestive Diseases and Sciences.

[114]  L. T. Angenent,et al.  Succession of microbial consortia in the developing infant gut microbiome , 2010, Proceedings of the National Academy of Sciences.

[115]  G. Eberl A new vision of immunity: homeostasis of the superorganism , 2010, Mucosal Immunology.

[116]  S. Nikfar,et al.  A Meta-Analysis on the Efficacy of Probiotics for Maintenance of Remission and Prevention of Clinical and Endoscopic Relapse in Crohn’s Disease , 2008, Digestive Diseases and Sciences.

[117]  E. Cario Commensal-Innate Immune Miscommunication in IBD Pathogenesis , 2012, Digestive Diseases.

[118]  P. Rosenstiel,et al.  Towards a molecular risk map--recent advances on the etiology of inflammatory bowel disease. , 2009, Seminars in immunology.

[119]  Robin C. Friedman,et al.  Growth and host interaction of mouse segmented filamentous bacteria in vitro , 2015, Nature.

[120]  Michael D. George,et al.  The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria. , 2014, Immunity.

[121]  R. Burcelin,et al.  Intestinal MicrobiOMICS to define health and disease in human and mice. , 2012, Current pharmaceutical biotechnology.

[122]  Dawn B. Beaulieu,et al.  Impact of Clostridium difficile on inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[123]  John Penders,et al.  Probiotics in the Management of Inflammatory Bowel Disease , 2012, Drugs.

[124]  U. Navaneethan,et al.  Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. , 2010, World journal of gastroenterology.

[125]  R. Sartor,et al.  Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(epsilon26) mice. , 2001, Gastroenterology.

[126]  J. Doré,et al.  Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray , 2010, Inflammatory bowel diseases.

[127]  M. Kamm,et al.  Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis , 2003, Gut.

[128]  D. Rubin,et al.  Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. , 2014, Journal of Crohn's & colitis.

[129]  Tomohiro Watanabe,et al.  NOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responses , 2004, Nature Immunology.

[130]  R. Sartor,et al.  Lactobacillus plantarum 299V in the Treatment and Prevention of Spontaneous Colitis in Interleukin-10-Deficient Mice , 2002, Inflammatory bowel diseases.

[131]  R. Hammer,et al.  Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. , 1996, The Journal of clinical investigation.

[132]  David M Richards,et al.  Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease , 2014, Clinical and experimental gastroenterology.

[133]  M. Neurath,et al.  Mouse models of inflammatory bowel disease. , 2007, Advanced drug delivery reviews.

[134]  P. Bork,et al.  Enterotypes of the human gut microbiome , 2011, Nature.

[135]  Ajay S. Gulati,et al.  Inflammatory Bowel Diseases Phenotype, C. difficile and NOD2 Genotype Are Associated with Shifts in Human Ileum Associated Microbial Composition , 2012, PloS one.

[136]  K. Lundin,et al.  Isolation of Mycobacterium avium Subspecies paratuberculosis Reactive CD4 T Cells from Intestinal Biopsies of Crohn's Disease Patients , 2009, PloS one.

[137]  M. Comalada,et al.  Preventative Effects of Lactulose in the Trinitrobenzenesulphonic Acid Model of Rat Colitis , 2005, Inflammatory bowel diseases.

[138]  Ellen S Pierce,et al.  C O M M E N T a R Y Open Access , 2022 .

[139]  N. Pace,et al.  Disease phenotype and genotype are associated with shifts in intestinal‐associated microbiota in inflammatory bowel diseases , 2011, Inflammatory bowel diseases.